Navigation Links
Abbott Announces Positive Nine-Month Results From the World's First,Clinical Trial of a Fully Bioabsorbable Drug Eluting Coronary Stent

improved radial strength, which is intended to maintain vessel expansion so blood can flow through.

"Not only is the ABSORB trial beginning to show that bioabsorbable technology, when applied to coronary stents, can work -- it can also provides a foundation for future interventional medical innovation," said John M. Capek, Ph.D., senior vice president, Abbott Vascular. "Five years ago, the technology and 'know-how' to make a fully functioning bioabsorbable drug eluting stent didn't exist, but every success in the ABSORB trial brings us one step closer to providing this important new treatment option to physicians for their patients."

About the ABSORB Clinical Trial

The ABSORB trial is a prospective, non-randomized (open label) study designed to enroll up to 60 patients in Belgium, Denmark, France, New Zealand, Poland and The Netherlands. Key endpoints of the study include assessments of safety; MACE and stent thrombosis (blood clot formation) rates at 30, 180 and 270 days, with an annual follow-up for up to five years, and successful deployment of the bioabsorbable drug eluting stent. Other key endpoints of the study include follow-up measurements assessed by X-ray angiography, intravascular ultrasound (IVUS), and state-of-the-art imaging modalities at 180 days and two years.

In March, six-month results from the first 30 patients in the ABSORB trial were presented at the of Cardiology conference, demonstrating no stent thrombosis and a low (3.3 percent, one patient) of Major Adverse Cardiac Events (MACE), such as heart attack or repeat interventional medical treatment.

For images of Abbott's investigational bioabsorbable stent and other information, please visit the company's online newsroom at http://www.abbottvascular.com/presskit.

About Abbott Vascular

Abbott Vascular, a division of Abbott, is one of the world's leading vascular care businesses.
'"/>




Page: 1 2 3

Related medicine technology :

1. Three Studies Suggest Abbotts Humira (adalimumab) May Improve Work Productivity in Patients with Rheumatoid Arthritis
2. Abbott Announces Continued Positive Results with Xience V Everolimus Eluting Coronary Stent in Spirit Clinical Trials
3. New Analysis of Data Shows Treatment With Abbotts Humira (Adalimumab) Significantly Reduced Disease-Related Hospitalization for Patients with Crohns Disease
4. Abbotts Investigational Treatment ABT-874 Shows Positive Results in Phase II Psoriasis Study
5. Abbott Researchers Focus on New Cutting-Edge Approaches in the Fight Against Cancer
6. Two Abbott Studies Reaffirm Carotid Artery Stenting as a Safe and Effective Treatment to Reduce Risk of Stroke
7. Abbott Announces Positive Six-Month Results From the Worlds First Clinical Trial of a Fully Bioabsorbable Drug-Eluting Coronary Stent
8. Abbotts Xience V Everolimus Eluting Coronary Stent Superior to Taxus Stent in Spirit III U.S. Pivotal Clinical Trial
9. Abbott to Present New Data Across its Vascular Portfolio at the American College of Cardiologys 56th Annual Scientific Session
10. Antisoma Announces Further Data From ASA404 Ovarian Cancer Trial
11. Neose Announces Presentation of Positive Preclinical Data on GlycoPEGylated Factor VIIa at the XXI Congress of the International Society on Thrombosis and Haemostasis
Post Your Comments:
(Date:5/22/2015)... Taskforce representing Canada,s living victims of ... the Minister and Health Canada have put into this program ... of the thalidomide survivors, and more than 70% of them ... annual adjustments for inflation. Certain of the thalidomide ... on the severity of their disability, tax free, with inflation ...
(Date:5/22/2015)... HILL, N.C. , May 22, 2015 /PRNewswire/ ... critical to pharmaceutical brand recognition and success. ... LLC conducted a study to provide pharmaceutical and ... of investment (FTEs and budget) that are being ... Pharmaceutical and biotech marketing managers can utilize this ...
(Date:5/22/2015)... , May 22, 2015 The leading ... $13 billion global cardiac rhythm management device market ... found that Medtronic, St. Jude Medical, Boston Scientific ... of this market segment. The healthcare market research ... , uses 2015 as a base year, providing ...
Breaking Medicine Technology:Effective Marketing Services Group Critical for Pharmaceutical Brand Recognition 2Kalorama: Top Companies Dominate Cardiac Defibrillator Market 2Kalorama: Top Companies Dominate Cardiac Defibrillator Market 3Kalorama: Top Companies Dominate Cardiac Defibrillator Market 4
(Date:5/23/2015)... 23, 2015 A live auction will be ... hospitals, surgery centers and other medical facilities around the United ... endoscopy, lab, radiology, surgery, anesthesia, exam and much more. ... and Thursday, May 28 starting at 9:00am CDT each day. ... N. 25th Avenue, Melrose Park, IL 60160. Anyone can ...
(Date:5/22/2015)... Pioneer Millworks, the largest reclaimed wood company ... with reclaimed wood, introducing their latest reclaimed wood products ... newest offerings, Vat 35, Reclaimed Teak , and ... America's largest design event. , “Designers, architects, builders, and ... to see and feel the variety of wood surfaces ...
(Date:5/22/2015)... 22, 2015 Following yesterday’s announcement that ... with US-based health brand Nature’s Way, Marc St-Onge has ... of Ascenta Skin is an integral part of the ... this opportunity to further develop Ascenta Skin into a ... Skin is a breakthrough, anti-aging skincare supplement featuring 6 ...
(Date:5/22/2015)... Family, friends, students, colleagues, mentors and fellow physicians ... D. Leffall, on Monday, May 18, with an 85th ... in the hospital’s Tower Auditorium. Leffall’s younger sister, 83-year-old ... to keep the secret. “I’d like to go in ... know something is up,” she said. , After more ...
(Date:5/22/2015)... Power Systems is proud to announce the sponsorship of ... is in his second year of racing in the professional ... Fire Department in Missoula, MT. He entered the triathlon scene ... career, he has had 15 1st Place finishes. In his ... in all seven of his 2014 races, including two 2nd ...
Breaking Medicine News(10 mins):Health News:Over 5,200 Lots of Medical Equipment Will Be Sold by Live Auction 2Health News:Pioneer Millworks to Reveal New Design Trends with Reclaimed Wood at Dwell on Design in LA 2Health News:Pioneer Millworks to Reveal New Design Trends with Reclaimed Wood at Dwell on Design in LA 3Health News:Ascenta Skin President Announces Plans to Grow Brand 2Health News:Colleagues Surprise Dr. LaSalle Leffall with 85th Birthday Celebration 2
... , Appointments may be made at H1N1inPA.com or by phone ... offer H1N1 flu vaccination clinics at 33 locations across Pennsylvania on ... is urged to make an appointment to attend. , "We ... wants it," said Health Secretary Everette James. "Even though flu activity ...
... whose moms took low doses , TUESDAY, Dec. 22 ... low-dose aspirin during pregnancy because they are at high ... at age 5, new research suggests. , Obstetricians sometimes ... to have such complications as fetal growth restriction (when ...
... Victoria and her European relatives, scientific detectives used a cutting-edge ... mutations, the tool can turn a single laboratory into a ... its own deep sequencer one of the first in ... Facility. The tool will add an important new capability ...
... , , Rally to Call on ... 22 Today, Tuesday, December 22, 2009 at Noon, Family ... front of Senator Mary Landrieu,s office in downtown Baton Rouge. ... asking her to reconsider her support for President Obama,s health ...
... Ohio, Dec. 22 AdCare Health Systems, Inc. (NYSE Amex: ... management company today reported that the warrants issued in connection with ... of the new warrants that were included in the Company,s recent ... current growth initiatives. , On December 21, 2009, the ...
... be used for artificial blood vessels in the future as ... synthetic materials currently used for bypass operations, reveals a thesis ... Produced by a bacterium known as Acetobacter xylinum ... pressure and works well with the body,s own tissue. The ...
Cached Medicine News:Health News:Department of Health to Offer H1N1 Vaccine Clinics for All Pennsylvanians 2Health News:Aspirin During Pregnancy May Help Preemies 2Health News:Aspirin During Pregnancy May Help Preemies 3Health News:Adding a genetic supertool 2Health News:FRC's Tony Perkins to Address Rally Today at Senator Mary Landrieu's Senate Office 2Health News:AdCare Health Systems' Warrant Holders Approve Amending Terms of their Public Warrants 2
... The assay is a direct competitive ... in human serum or plasma. A specific ... it available for antibody binding. Estradiol then ... to fluorescein isothiocyanate (FITC) and alkaline phosphatase ...
... the most potent, naturally secreted estrogen and ... ovary [1]. In the ovary, estradiol is ... a less potent estrogen derived from androstenedione. ... body tissues. In men, small amounts of ...
... troponin I (cTnI) has been useful in ... Emergency Departments (ED) with chest pain. 18-20 ... when blood levels of sensitive and specific ... isoenzyme of creatine kinase (CK-MB), and myoglobin, ...
The second-generation Dade Behring Acute Care Troponin I (cTnI) method is the first FDA cleared high sensitivity cTnI assay with the low-end precision necessary to meet the ESC/ACC guidelines (CV <10...
Medicine Products: